获得性全身性脂肪营养不良:抗PD-1免疫相关糖尿病的新病因
本文报告首例由免疫检查点治疗诱发的获得性全身性脂肪营养不良(AGL)病例。一名接受纳武利尤单抗治疗的转移性黑色素瘤62岁女性出现严重高血糖、高甘油三酯血症和非酒精性脂肪性肝炎,伴快速进展的全身性皮下脂肪丢失。糖尿病与严重胰岛素抵抗及血浆瘦素检测不到相关,皮下活检显示萎缩脂肪组织被细胞毒性CD8+ T淋巴细胞浸润和纤维化。结论认为AGL是抗PD-1治疗的另一免疫相关不良事件,导致严重胰岛素抵抗相关并发症。
要点
- 抗PD-1治疗可诱发AGL,表现为全身皮下脂肪快速丢失。
- AGL相关糖尿病以严重胰岛素抵抗和血浆瘦素检测不到为特征。
- 皮下活检可见CD8+ T淋巴细胞浸润和纤维化,提示免疫介导。
核心结论
- AGL是抗PD-1治疗的另一免疫相关不良事件,导致严重胰岛素抵抗相关并发症。
研究设计与样本
- 本文描述首例由免疫检查点治疗诱发的获得性全身性脂肪营养不良病例。
主要发现
- 62岁转移性黑色素瘤女性接受纳武利尤单抗治疗后出现严重高血糖、高甘油三酯血症和非酒精性脂肪性肝炎。
- 患者表现为快速进展的全身性皮下脂肪组织丢失。
- 糖尿病与严重胰岛素抵抗及血浆瘦素检测不到相关。
- 皮下活检显示萎缩脂肪组织被细胞毒性CD8+ T淋巴细胞浸润和纤维化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Anti-programmed cell death-1 (anti-PD-1) antibodies have revolutionized advanced cancer therapy. Anti-PD-1 therapy is responsible for immune-related adverse events, with frequent endocrine manifestations, including acute-onset type 1 diabetes. Acquired generalized lipodystrophy (AGL) is a rare disease, believed to be immune mediated, characterized by loss of adipose tissue and insulin resistance-associated complications. RESEARCH DESIGN AND METHODS: We describe the first reported case of AGL induced by immune checkpoint therapy. RESULTS: A 62-year-old woman with metastatic melanoma treated with nivolumab was referred for major hyperglycemia, hypertriglyceridemia, and nonalcoholic steatohepatitis. She had presented with a rapidly progressive generalized loss of subcutaneous adipose tissue. Diabetes was associated with severe insulin resistance and undetectable plasma leptin. Subcutaneous biopsy revealed atrophic adipose tissue infiltrated with cytotoxic CD8+ T lymphocytes and fibrosis. CONCLUSIONS: AGL is an additional immune-related adverse event of anti-PD-1 therapy that leads to severe insulin resistance-associated complications.
引用
- Jehl A, Cugnet-Anceau C, Vigouroux C, et al. Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes. Diabetes Care. 2019. PMID: 31434650. doi:10.2337/dc18-2535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。